Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Esplugues De Llobregat – page 165

3 740 clinical trials in Esplugues De Llobregat, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Esplugues De Llobregat at a glance
3 740
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 740 trials in Esplugues De Llobregat

Open in trial search

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Serplulimab
  • Sponsor:Shanghai Henlius Biotech Inc.

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Efficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Pharmacokinetic, Safety, and Efficacy Evaluation of ASTX727 and Venetoclax in Adult Patients with Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Gilead Sciences Inc.

Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Neoplasm malignant

Not recruiting

Phase 1 Study of ADCT-901 in Patients with Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Antitumor Activity

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ADCT-901
  • Sponsor:ADC Therapeutics SA

Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Esplugues De Llobregat

What the registry says about research in the country

01 Pediatric Oncology Research

Innovative clinical trials focusing on pediatric cancers include studies for neuroblastoma, hepatic tumors, and various sarcomas. Research efforts target both primary and refractory disease states.

  • High-risk neuroblastoma treatments
  • Hepatoblastoma and hepatocellular carcinoma therapies
  • Ewing sarcoma management

Studies are evaluating novel therapeutic approaches for improving patient outcomes in challenging pediatric cancers.

02 Rare Genetic Disorders

Research initiatives addressing rare genetic conditions are exploring new treatment options for conditions affecting children and young adults.

  • Duchenne Muscular Dystrophy
  • Angelman Syndrome
  • Prader-Willi Syndrome
  • Hunter Syndrome

These trials aim to evaluate innovative therapies targeting specific genetic mechanisms.

03 Respiratory and Immunological Studies

Clinical research focusing on respiratory conditions and immunological responses, particularly in pediatric populations.

  • RSV prevention in high-risk infants
  • Allergic rhinitis treatments
  • Bronchopulmonary dysplasia management

Studies emphasize both preventive measures and therapeutic interventions for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.